Overview
Calibrate focuses on sustainable weight loss by improving metabolic health rather than traditional dieting. It delivers a subscription-based program, commonly covered by employers, combining incremental habit changes with GLP-1 medication that targets biology to reduce inflammation, regulate digestion, enhance metabolic function, and lower cardiovascular risk. The program reports real-world results of about 15% sustained weight loss, distinguishing it from typical clinical trial claims. Clients are primarily corporations seeking employee wellness benefits, though individuals can subscribe too. The company offers a money-back guarantee if promised results aren’t achieved. Overall, Calibrate aims to help people lose weight and improve metabolic health in a practical, maintainable way, scaling through employer-based wellness programs.
Work here?Claim your company
Simplify's take
What believers are saying
- Calibrate said February 19, 2026 enterprise clients doubled and 90% of business now enterprise.
- The company expects profitability for the first time, driven by employer demand and PBM partnerships.
- May 5, 2026 data showed 16% average first-year weight loss and sustained four-year outcomes.
What critics are saying
- BBB listed 154 complaints through March 13, 2026, signaling persistent refund friction.
- Madryn’s 2023 takeover and restructuring left Calibrate dependent on private-equity discipline.
- Enterprise obesity management faces direct competition from Wegovy and Zepbound benefit programs, compressing margins quickly.
What makes Calibrate unique
- Calibrate’s 2026 Results Report tracks 50,000 members across nearly six years.
- Its enterprise pivot makes employers, health plans, and PBMs the core distribution channel.
- Clinical care, coaching, and GLP-1 stewardship sit on one integrated platform.
Help us improve and share your feedback! Did you find this helpful?
